争议性批准新型药物治疗老年痴呆症。
Controversial Approval of New Drug to Treat Alzheimer's Disease.
机构信息
Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch :
出版信息
Am J Nurs. 2021 Oct 1;121(10):22-23. doi: 10.1097/01.NAJ.0000794244.40800.99.
Abstract
Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).This drug's approval has been highly contentious in the medical and scientific community owing to contradictory study findings and the FDA's advisory panel not recommending its approval.
摘要
阿杜卡玛单抗（Aduhelm）是自 2003 年以来首个获批用于治疗阿尔茨海默病的新药，已获得美国食品药品监督管理局（FDA）的加速批准。由于研究结果相互矛盾，且 FDA 顾问小组不建议批准该药物，该药物的获批在医学和科学界引起了广泛争议。
相似文献
1
Controversial Approval of New Drug to Treat Alzheimer's Disease.争议性批准新型药物治疗老年痴呆症。
Am J Nurs. 2021 Oct 1;121(10):22-23. doi: 10.1097/01.NAJ.0000794244.40800.99.
2
Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.阿杜卡奴单抗（商品名为 Aduhelm）的获批可能基于对 PET 成像数据的误解。
J Alzheimers Dis. 2021;84(4):1457-1460. doi: 10.3233/JAD-215275.
3
Ignoring the Experts: Implications of the FDA's Aduhelm Approval.无视专家意见：FDA 批准阿杜卡玛单抗的影响。
Am J Law Med. 2022 Mar;48(1):108-133. doi: 10.1017/amj.2022.15.
4
Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.阿尔茨海默病的争议与进展——阿杜卡单抗获美国食品药品监督管理局批准
N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.
5
Can we learn lessons from the FDA's approval of aducanumab?我们能否从 FDA 批准 aducanumab 中吸取教训？
Nat Rev Neurol. 2021 Nov;17(11):715-722. doi: 10.1038/s41582-021-00557-x. Epub 2021 Sep 17.
6
Aducanumab for Alzheimer's disease: A regulatory perspective.阿杜卡奴单抗治疗阿尔茨海默病：监管视角。
Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.
7
Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.阿杜卡努单抗获批用于治疗阿尔茨海默病——美国食品药品监督管理局的观点。
JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. doi: 10.1001/jamainternmed.2021.4607.
8
Aducanumab (Aduhelm) for Alzheimer's disease.用于治疗阿尔茨海默病的阿杜卡努单抗（阿杜海姆）
Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.
9
Revisiting FDA Approval of Aducanumab.重新审视阿杜卡努单抗的美国食品药品监督管理局批准情况。
N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.
10
Alzheimer's and Aducanumab: Unjust Profits and False Hopes.阿尔茨海默病和 aducanumab：不义之财与虚假希望。
Hastings Cent Rep. 2021 Jul;51(4):9-11. doi: 10.1002/hast.1264. Epub 2021 Jun 22.
引用本文的文献
1
Ethanolic Extract of Roots and Its Bioactive Compound, Oleamide, Prevented Amyloid β-Induced Oxidative Stress and Improved Behavioral Tests in Mice.根的乙醇提取物及其生物活性化合物油酰胺可预防淀粉样蛋白β诱导的氧化应激并改善小鼠行为测试。
Int J Mol Sci. 2025 Apr 29;26(9):4214. doi: 10.3390/ijms26094214.
2
Intravenous treatment with a molecular chaperone designed against β-amyloid toxicity improves Alzheimer's disease pathology in mouse models.静脉注射一种针对β-淀粉样蛋白毒性的分子伴侣治疗可改善小鼠模型的阿尔茨海默病病理。
Mol Ther. 2023 Feb 1;31(2):487-502. doi: 10.1016/j.ymthe.2022.08.010. Epub 2022 Aug 17.
3
Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease.淀粉样肽和分泌酶在阿尔茨海默病的发病机制和治疗中的作用。
Biomolecules. 2022 Jul 17;12(7):996. doi: 10.3390/biom12070996.
Zotero 插件